SOPHiA GENETICS SA Debt to Equity Ratio 2020-2025 | SOPH
Current and historical debt to equity ratio values for SOPHiA GENETICS SA (SOPH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. SOPHiA GENETICS SA debt/equity for the three months ending June 30, 2025 was 0.78.
| SOPHiA GENETICS SA Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-06-30 | $0.10B | $0.08B | 1.32 |
| 2025-03-31 | $0.06B | $0.09B | 0.71 |
| 2024-12-31 | $0.06B | $0.10B | 0.61 |
| 2024-09-30 | $0.06B | $0.11B | 0.57 |
| 2024-06-30 | $0.06B | $0.12B | 0.49 |
| 2024-03-31 | $0.05B | $0.13B | 0.36 |
| 2023-12-31 | $0.06B | $0.15B | 0.36 |
| 2023-09-30 | $0.05B | $0.16B | 0.30 |
| 2023-06-30 | $0.05B | $0.17B | 0.30 |
| 2023-03-31 | $0.05B | $0.19B | 0.26 |
| 2022-12-31 | $0.04B | $0.20B | 0.22 |
| 2022-09-30 | $0.05B | $0.21B | 0.22 |
| 2022-06-30 | $0.05B | $0.23B | 0.22 |
| 2022-03-31 | $0.05B | $0.25B | 0.18 |
| 2021-12-31 | $0.05B | $0.28B | 0.16 |
| 2021-09-30 | $0.05B | $0.29B | 0.16 |
| 2021-06-30 | $0.03B | $0.07B | 0.46 |
| 2021-03-31 | $0.03B | $0.08B | 0.36 |
| 2020-12-31 | $0.03B | $0.10B | 0.31 |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.03B | $0.02B | 1.32 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.312B | $0.065B |
| SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. SOPHiA GENETICS SA is based in BOSTON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $49.025B | 59.82 |
| Tempus AI (TEM) | United States | $12.432B | 0.00 |
| Doximity (DOCS) | United States | $9.874B | 40.87 |
| Hims & Hers Health (HIMS) | United States | $9.049B | 73.61 |
| IRhythm Technologies (IRTC) | United States | $5.681B | 0.00 |
| Hinge Health (HNGE) | United States | $3.475B | 0.00 |
| Privia Health (PRVA) | United States | $2.991B | 187.08 |
| Heartflow (HTFL) | United States | $2.850B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.632B | 43.55 |
| 10x Genomics (TXG) | United States | $2.065B | 0.00 |
| Enovis (ENOV) | United States | $1.802B | 9.46 |
| Omnicell (OMCL) | United States | $1.665B | 34.05 |
| Azenta (AZTA) | United States | $1.405B | 61.32 |
| Phreesia (PHR) | United States | $1.363B | 0.00 |
| Schrodinger (SDGR) | United States | $1.347B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.307B | 0.00 |
| Claritev (CTEV) | United States | $0.943B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.877B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.621B | 0.00 |
| Evolent Health (EVH) | United States | $0.592B | 0.00 |
| Talkspace (TALK) | United States | $0.585B | 117.67 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.458B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.381B | 0.00 |
| Carlsmed (CARL) | United States | $0.324B | 0.00 |
| TruBridge (TBRG) | United States | $0.293B | 13.45 |
| CapsoVision (CV) | United States | $0.255B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.216B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.210B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.192B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.190B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.172B | 0.00 |
| CareCloud (CCLD) | United States | $0.140B | 7.70 |
| EUDA Health Holdings (EUDA) | Singapore | $0.116B | 0.00 |
| Outset Medical (OM) | United States | $0.113B | 0.00 |
| Pulmonx (LUNG) | United States | $0.085B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.075B | 0.00 |
| American Well (AMWL) | United States | $0.063B | 0.00 |
| HeartBeam (BEAT) | United States | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.054B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.038B | 0.00 |
| 111 (YI) | China | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.033B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.028B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.020B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Movano (MOVE) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |